‘Working to improve research ecosystem’: BHU conveys regret
Researchers from the Banaras Hindu University that conducted a study on the safety of Covaxin have conveyed their regret to the Indian Council of Medical Research for acknowledging the support of the apex biomedical research regulator without proper authorisation, people familiar with the matter said. “Additionally, the Institute of Medical Sciences is also working on further strengthening and improving its research ecosystem.” ICMR on Monday distanced itself from the BHU study that raised concerns on the safety of Bharat Biotech’s Covid vaccine Covaxin, and threatened legal action against the study’s authors for acknowledging ICMR’s support for a poorly designed study without its consent. ICMR chief Rajiv Bahl wrote to the researchers, criticizing the research paper entitled “Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India”. Nearly one-third of the 926 participants in the study who received Hyderabad-based vaccine manufacturer’s Covaxin reported “adverse events of special interest ”, the paper stated.
Bharat Biotech's Covaxin effective against double mutant Covid strain: ICMR study
Discover Related
ICMR cancer study is 'alarming': Kerala begins year-long awareness campaign
India’s winding road to ‘#EndTB’
India sets up the first diabetes biobank in Chennai. Here's why this is significant
Time to step up the fight against AMR
JNU scientists make big discovery that could change malaria, Covid-19 treatment
CSIR Gives Cutting Edge Tech with Eye on Future
ICMR gets U.N. award for successes in control of non-communicable diseases
Solving the challenge of drug-resistant TB in India
ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR
BHU’s Covaxin safety study riddled with major limitations
1 in 3 Covaxin takers reported adverse events, BHU study claims
BHU study: Over 30 per cent of Covaxin recipients report adverse events
‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
ICMR institutes to take on broader role in healthcare
Ayush ministry pushing institutes, wellness centres to conduct research
Union ayush, health ministers to announce multi-centre clinical trial on anaemia
ICMR starts revising current National Essential Diagnostics List for first time
Burying the fallacy of vaccine sceptics
Indian Medicine Can Lead Cancer Cure? American Entrepreneur's Big Claim | HTLS 2023
AIIMS to have integrated health study centres
'Antibody Use Not Approved, But...': ICMR on Treatment for Nipah Virus Outbreak